Former senior executive at Stada Arzneimittel AG
- Stada’s underlying Q1 2022 performance, margin evolution and EBITDA adjustments
- Russia-Ukraine conflict’s impact on Stada – portfolio review, regional performance outlook and impact on wider market
- Stada generics – price, volume and LOE (loss of exclusivity) dynamics, key brand performance and Germany performance and tenders case study
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.